Cargando…

Chimeric Antigen Receptor T-Cell Therapy in Lung Cancer: Potential and Challenges

Chimeric antigen receptor T (CAR-T) cell therapy has exhibited a substantial clinical response in hematological malignancies, including B-cell leukemia, lymphoma, and multiple myeloma. Therefore, the feasibility of using CAR-T cells to treat solid tumors is actively evaluated. Currently, multiple ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xiao, Bu-Fan, Zhang, Jing-Tao, Zhu, Yu-Ge, Cui, Xin-Run, Lu, Zhe-Ming, Yu, Ben-Tong, Wu, Nan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591168/ https://www.ncbi.nlm.nih.gov/pubmed/34790207 http://dx.doi.org/10.3389/fimmu.2021.782775

Ejemplares similares

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions
por: Zhang, Peng, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cell Therapy in Glioblastoma: Current and Future
por: Li, Long, et al.
Publicado: (2020)

Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2017)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T cells applied to solid tumors
por: Zhou, Zhongguo, et al.
Publicado: (2022)

Corrigendum: Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications
por: Mirzaei, Hamid R., et al.
Publicado: (2019)

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities
por: Chen, Long, et al.
Publicado: (2022)

Utility and Drawbacks of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Lung Cancer
por: Kandra, Prameela, et al.
Publicado: (2022)

New Chimeric Antigen Receptor Design for Solid Tumors
por: Wang, Yuedi, et al.
Publicado: (2017)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells
por: Elahi, Reza, et al.
Publicado: (2018)

Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward
por: Jafarzadeh, Leila, et al.
Publicado: (2020)

Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors
por: Kosti, Paris, et al.
Publicado: (2018)

Efficient derivation of chimeric-antigen receptor-modified T(SCM) cells
por: Kranz, Emiko, et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022)

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
por: Chmielewski, Markus, et al.
Publicado: (2013)

Bibliometric Analysis of Chimeric Antigen Receptor-Based Immunotherapy in Cancers From 2001 to 2021
por: Ou, Zhanpeng, et al.
Publicado: (2022)

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
por: Hermanson, David L., et al.
Publicado: (2015)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
por: Mehta, Rohtesh S., et al.
Publicado: (2018)

Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing
por: Liu, Jie, et al.
Publicado: (2019)

Chimeric Antigen Receptor (CAR) Regulatory T-Cells in Solid Organ Transplantation
por: Gille, Ilse, et al.
Publicado: (2022)

Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia
por: Schorr, Christopher, et al.
Publicado: (2022)

Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes
por: Nanjireddy, Priyanka Maridhi, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment
por: Yan, Zhiling, et al.
Publicado: (2021)

Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen
por: Timmers, Marijke, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
por: Xu, Caili, et al.
Publicado: (2022)

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia
por: Tomuleasa, Ciprian, et al.
Publicado: (2018)

A Novel Treatment for Ewing’s Sarcoma: Chimeric Antigen Receptor-T Cell Therapy
por: Lin, Zili, et al.
Publicado: (2021)

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
por: Zhang, Hao, et al.
Publicado: (2022)

Infection Temperature Affects the Phenotype and Function of Chimeric Antigen Receptor T Cells Produced via Lentiviral Technology
por: Jin, Xin, et al.
Publicado: (2021)

Differences in the phenotypes and transcriptomic signatures of chimeric antigen receptor T lymphocytes manufactured via electroporation or lentiviral transfection
por: Niu, Anna, et al.
Publicado: (2023)

Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance
por: Zhang, Qunfang, et al.
Publicado: (2018)

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don’t Forget the Fuel
por: Irving, Melita, et al.
Publicado: (2017)

Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28
por: Muller, Yannick D., et al.
Publicado: (2021)

Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy
por: Sterner, Robert C., et al.
Publicado: (2022)

Programmable Attenuation of Antigenic Sensitivity for a Nanobody-Based EGFR Chimeric Antigen Receptor Through Hinge Domain Truncation
por: McComb, Scott, et al.
Publicado: (2022)

Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model
por: Wang, Yanan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cfbutbko8d352086h8p9dj0eqi